Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor

被引:64
作者
Schmidt, Karsten [1 ]
Prakash, Thazha P. [1 ]
Donner, Aaron J. [1 ]
Kinberger, Garth A. [1 ]
Gaus, Hans J. [1 ]
Low, Audrey [1 ]
Ostergaard, Michael E. [1 ]
Bell, Melanie [1 ]
Swayze, Eric E. [1 ]
Seth, Punit P. [1 ]
机构
[1] Ionis Pharmaceut Inc, 2855 Gazelle Court, Carlsbad, CA 92010 USA
关键词
TARGETED DELIVERY; MEDIATED ENDOCYTOSIS; HIGH-AFFINITY; MICE LACKING; IN-VIVO; HEPATOCYTES; SUBUNIT; LIGAND; LIVER; OLIGODEOXYNUCLEOTIDES;
D O I
10.1093/nar/gkx060
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs similar to 30-fold in the clinic (1). In order to fully characterize the effect of GalNAc valency, oligonucleotide length, flexibility and chemical composition on ASGR binding, we tested and validated a fluorescence polarization competition binding assay. The ASGR binding, and in vitro and in vivo activities of 1, 2 and 3 GalNAc conjugated single stranded and duplexed ASOs were studied. Two and three GalNAc conjugated single stranded ASOs bind the ASGR with the strongest affinity and display optimal in vitro and in vivo activities. 1 GalNAc conjugated ASOs showed 10-fold reduced ASGR binding affinity relative to three GalNAc ASOs but only 2-fold reduced activity in mice. An unexpected observation was that the ASGR also appears to play a role in the uptake of unconjugated phosphorothioate modified ASOs in the liver as evidenced by the loss of activity of GalNAc conjugated and unconjugated ASOs in ASGR knockout mice. Our results provide insights into how backbone charge and chemical composition assist in the binding and internalization of highly polar anionic single stranded oligonucleotides into cells and tissues.
引用
收藏
页码:2294 / 2306
页数:13
相关论文
共 40 条
  • [1] RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
    Bennett, C. Frank
    Swayze, Eric E.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2010, 50 : 259 - 293
  • [2] HIGH-AFFINITY LIGAND-BINDING TO SUBUNIT H1 OF THE ASIALOGLYCOPROTEIN RECEPTOR IN THE ABSENCE OF SUBUNIT H2
    BIDER, MD
    CESCATO, R
    JENO, P
    SPIESS, M
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 230 (01): : 207 - 212
  • [3] Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo
    Biessen, EAL
    Vietsch, H
    Rump, ET
    Fluiter, K
    Kuiper, J
    Bijsterbosch, MK
    Van Berkel, TJC
    [J]. BIOCHEMICAL JOURNAL, 1999, 340 : 783 - 792
  • [4] SYNTHESIS OF CLUSTER GALACTOSIDES WITH HIGH-AFFINITY FOR THE HEPATIC ASIALOGLYCOPROTEIN RECEPTOR
    BIESSEN, EAL
    BEUTING, DM
    ROELEN, HCPF
    VANDEMAREL, GA
    VANBOOM, JH
    VANBERKEL, TJC
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (09) : 1538 - 1546
  • [5] The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit
    Braun, JR
    Willnow, TE
    Ishibashi, S
    Ashwell, G
    Herz, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (35) : 21160 - 21166
  • [6] BROWN DA, 1994, J BIOL CHEM, V269, P26801
  • [7] Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B
    Crooke, Stanley T.
    Geary, Richard S.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (02) : 269 - 276
  • [8] Asialoglycoprotein receptor mediated hepatocyte targeting - Strategies and applications
    D'Souza, Anisha A.
    Devarajan, Padma V.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2015, 203 : 126 - 139
  • [9] Duff RJ, 2000, METHOD ENZYMOL, V313, P297
  • [10] Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
    Eckstein, F
    [J]. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2000, 10 (02): : 117 - 121